Skip to main navigation
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

SEC Filings

  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
    • Quarterly and Annual Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
Filing date Form Description View
May 5, 2022 4

Statement of changes in beneficial ownership of securities

0001808805-22-000052.pdf
0001808805-22-000052.rtf
0001808805-22-000052.xls
View HTML
May 3, 2022 8-K

Report of unscheduled material events or corporate event

0001808805-22-000044.pdf
0001808805-22-000044.rtf
0001808805-22-000044.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 3, 2022 10-Q

Quarterly report which provides a continuing view of a company's financial position

0001808805-22-000046.pdf
0001808805-22-000046.rtf
0001808805-22-000046.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 3, 2022 424B3

Form of prospectus reflecting facts events constituting substantive change from last form

0001808805-22-000048.pdf
0001808805-22-000048.rtf
0001808805-22-000048.xls
View HTML
Apr 28, 2022 DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

0001808805-22-000041.pdf
0001808805-22-000041.rtf
0001808805-22-000041.xls
View HTML
Apr 28, 2022 DEFA14A

Additional proxy soliciting materials - definitive

0001808805-22-000042.pdf
0001808805-22-000042.rtf
0001808805-22-000042.xls
View HTML
Apr 15, 2022 3/A

An amendment to a 3 filing. Non-EDGAR filing

0001808805-22-000037.pdf
0001808805-22-000037.rtf
0001808805-22-000037.xls
View HTML
Apr 13, 2022 3

Initial filing by director officer or owner of more than ten percent.

0001808805-22-000035.pdf
0001808805-22-000035.rtf
0001808805-22-000035.xls
View HTML
Mar 31, 2022 8-K

Report of unscheduled material events or corporate event

0001808805-22-000030.pdf
0001808805-22-000030.rtf
0001808805-22-000030.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 31, 2022 3

Initial filing by director officer or owner of more than ten percent.

0001808805-22-000031.pdf
0001808805-22-000031.rtf
0001808805-22-000031.xls
View HTML

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page Next ›
  • Last page Last »
Displaying 61 - 70 of 191 results

Data provided by Kaleidoscope.

Sign-up for updates

Sign Up

Nautilus Biotechnology

 

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

 

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

Nautilus Biotechnology

 

linkedin      twitter

info@nautilus.bio
+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.

Privacy Policy | Terms